As an orally available inhibitor of endothelin-1, which has been implicated in the pathogenesis of vascular disease in systemic sclerosis (SSc), bosentan is widely used as first-line therapy for ...

Bosentan is a dual endothelin-1-receptor antagonist that effectively treats idiopathic PAH and PAH related to connective tissue disease. Following preliminary trials of bosentan for the treatment ...